Helicobacter pylori and Microcirculation

被引:9
|
作者
Suzuki, Hidekazu [1 ]
Suzuki, Masayuki
Imaeda, Hiroyuki [2 ]
Hibi, Toshifumi
机构
[1] Keio Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Sch Med,Shinjuku Ku, Tokyo 1608585, Japan
[2] Keio Univ Hosp, Ctr Diagnost & Therapeut Endoscopy, Shinjuku Ku, Tokyo, Japan
基金
日本学术振兴会;
关键词
microcirculation; H; pylori; gastric mucosa; endothelial cell; platelet; leukocyte; cytokine; GASTRIC-MUCOSAL MICROCIRCULATION; CENTRAL SEROUS CHORIORETINOPATHY; ENDOTHELIAL GROWTH-FACTOR; UREASE IMMUNOGLOBULIN-Y; ALPHA-METHYL HISTAMINE; CORONARY HEART-DISEASE; MONGOLIAN-GERBILS; IN-VIVO; CONGESTIVE GASTROPATHY; LEUKOCYTE ACTIVATION;
D O I
10.1080/10739680902949953
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Microcirculation is one of the susceptible targets in the pathogenesis of disorders caused by exogenous pathogens, such as the well-known bacterium, Helicobacter pylori (Hp). While extensive studies have been published on the kinetics of Hp infection, only a few have dealt with the microcirculatory aspects of Hp-induced disorders. This review summarizes the recent developments in the elucidation of the pathophysiology of disorders. This review summarizes the recent developments in the elucidation of the pathophysiology of disorders caused by Hp infection, focusing on the microcirculatory aspect. Animal and human studies were systematically reviewed to identify published data on the microcirculatory aspects of Hp infection. This updated summary of the microcirculatory aspects of Hp-induced disorders illustrates potential approaches that might be used to clarify the pathophysiology of the gastric and extragastric sequelae of Hp infection and the therapeutic strategies that could be adopted. Microcirculation (2009) 16, 547-558. doi:10.1080/10739680902949953
引用
收藏
页码:547 / 558
页数:12
相关论文
共 50 条
  • [41] Helicobacter pylori: Ulcers and more: The beginning of an era
    Lacy, BE
    Rosemore, J
    JOURNAL OF NUTRITION, 2001, 131 (10) : 2789S - 2793S
  • [42] The prevention of gastric cancer by Helicobacter pylori eradication
    Argueta, Erick A.
    Moss, Steven F.
    CURRENT OPINION IN GASTROENTEROLOGY, 2021, 37 (06) : 625 - 630
  • [43] Seroprevalence of Helicobacter pylori infection in patients with lymphoma
    Cuttner, J
    Werther, JL
    McGlynn, P
    Chen, AL
    Bodian, C
    Ogata, S
    Strauchen, J
    Troy, K
    Itzkowitz, S
    LEUKEMIA & LYMPHOMA, 2001, 40 (5-6) : 591 - 597
  • [44] The Epidemiology of Helicobacter pylori and Public Health Implications
    Azevedo, Nuno F.
    Huntington, Janis
    Goodman, Karen J.
    HELICOBACTER, 2009, 14 : 1 - 7
  • [45] Designing Helicobacter pylori as an Anticancer Bacterial Vector
    Zhang, Selina
    Chen, Jake Y.
    14TH ACM CONFERENCE ON BIOINFORMATICS, COMPUTATIONAL BIOLOGY, AND HEALTH INFORMATICS, BCB 2023, 2023,
  • [46] Helicobacter pylori: enemy, commensal or, sometimes, friend?
    Whalen, Michael B.
    Massidda, Orietta
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2015, 9 (06): : 674 - 678
  • [47] Helicobacter pylori in children
    Sustmann, Andrea
    Okuda, Masumi
    Koletzko, Sibylle
    HELICOBACTER, 2016, 21 : 49 - 54
  • [48] HELICOBACTER PYLORI AND RELATED GASTROINTESTINAL SYSTEM DISEASES
    Yilmaz, Omer
    Okcu, Nihat
    EURASIAN JOURNAL OF MEDICINE, 2006, 38 (01) : 13 - 17
  • [49] Inflammation, immunity, and vaccines for Helicobacter pylori infection
    Velin, Dominique
    Straubinger, Kathrin
    Gerhard, Markus
    HELICOBACTER, 2016, 21 : 26 - 29
  • [50] Helicobacter pylori infection in Europe: current perspectives
    O'Connor, Anthony
    O'Morain, Colm
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 7 (06) : 541 - 548